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Atherosclerotic peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic
arterial disease elsewhere in the circulation and a cluster of cardiovascular risk factors inducing atheroma progression
and/or thrombotic complications. Because of these strong clinical associations, especially with coronary heart disease, the
ankle-brachial pressure index (ABPI) is of prognostic significance. The clinical management of IC should include relief
of symptoms combined with prevention of secondary cardiovascular complications, e.g. acute thrombotic events causing
limb- or life-threatening ischaemia, which are often due to atherosclerotic plaque rupture leading to thrombotic vessel
occlusion. Many patients with PAD do not receive an optimum package of secondary prevention, tailored to include
maximum cholesterol reduction, BP and glycaemic control, ACE inhibition and single or combination anti-platelet
therapy. This review considers recent information from large secondary prevention trials, e.g. the PAD subgroups within
the HOPE, CAPRIE and statin studies. Slowing progression of atherosclerosis, and inducing stabilisation and regression
of atheromatous plaques, is now feasible using long-term combination drug therapy. The phrase ‘‘conservative therapy’’,
popular among vascular surgeons, implies a passive minimal-intervention strategy of surveillance and lifestyle advice;
such terminology is perhaps no longer appropriate since considerable improvements in survival are likely to accrue if all
patients with PAD, especially those with low ABPI, receive vigorous, titrated medical therapies, tailored to individual
patients, as part of an evidence-based secondary prevention regime.
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Introduction survival, whereas for the corresponding disorder in the
heart (stable angina) coronary artery by-pass grafting
Medical and surgical therapies for patients with in- may be indicated for relief of angina (e.g. when max-
termittent claudication (IC) have two separate but imal medical therapy fails) and/or prolongation of life
complementary objectives: (1) symptom relief, i.e. im- expectancy (e.g. when there is triple vessel disease and
proved walking distance and quality of life, and (2) impaired left ventricular function).2 Similarly, medical
prevention of secondary vascular complications, espe- therapies such as aspirin have no effect on arterial
cially plaque rupture leading to acute thrombotic symptoms, either angina or intermittent claudication,
events that may be limb-threatening and/or life-threat- but antiplatelet therapy reduces the risk of secondary
ening. Survival is related to the severity of peripheral thrombotic complications in the heart, brain and lower
arterial disease (Fig. 1),1 and different treatment strat- limb, which in turn prolongs survival when used as
egies for IC (both medical and surgical) have variable secondary prevention.
effects on each of these therapeutic goals (Fig. 2). For Although the majority of patients with IC do not
example, lower limb revascularisation in those patients require surgical intervention, there is good evidence
with Fontaine stage II may improve the symptoms that a package of long-term medical therapies, tailored
of IC, but surgical procedures do not affect overall to the needs of individual patients, provides effective
secondary prevention to modify atherosclerotic disease
progression in major arteries (i.e. plaque stabilisation
∗ Please address all correspondence to: R. Donnelly, Division of and/or regression) and in particular to reduce the riskVascular Medicine, University of Nottingham, Derbyshire Royal
Infirmary, Derby DE1 2QY, U.K. of acute thrombotic complications such as acute limb
1078–5884/02/020100+08 $35.00/0  2002 Elsevier Science Ltd. All rights reserved.
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Clinical Trials of Secondary Prevention
Application to patients with symptomatic PAD
Because the presence of IC signifies an increased risk of
mortality, both from lower limb vascular complications
(e.g. acute limb ischaemia, ulceration and gangrene)
and non-limb vascular complications (e.g. acute myo-
cardial infarction, stroke or sudden death), it is es-
sential that patients with IC are given appropriate
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secondary prevention. Unfortunately, most of the evi-
Fig. 1. ABPI is a prognostic marker. Patient survival according to dence pertaining to this patient population has been
ABPI, reflecting the strong association with silent or symptomatic extrapolated from large secondary prevention studiesarterial disease in the heart and brain. Adapted from [1].
undertaken primarily in patients with symptoms of
coronary heart disease (CHD), some of whom also
had PAD, but in practice all patients with clinical
evidence of atherosclerosis – irrespective of whether
the earliest symptoms of arterial stenosis localise to
the heart, brain or legs – merit a package of secondary
prevention treatments (Fig. 2).
Smoking cessation
Cigarette smoking is the single most powerful risk
factor associated with the aetiology and clinical pro-
gression of PAD. Among patients with IC, continued
smoking is clearly associated with a greater likelihood
of developing disabling claudication, limb-threatening
MANAGEMENT OF
INTERMITTENT CLAUDICATION
SYMPTOM RELIEF SECONDARY PREVENTION
TO PROLONG SURVIVAL
• Exercise
• Medical therapy
• Revascularisation
• Anti-platelet therapy
• Smoking cessation: NRT
• Statin: LDL-cholesterol
   < 3 mM
•BP control: BP < 140/85
• ACE inhibitor
•Glycaemic: HBA1C < 7%
+
ischaemia, amputation and the need for surgical inter-Fig. 2. Medical and surgical therapies that relieve symptoms of IC
vention.3,4 In addition, patency rates and survival areshould be combined with separate treatments that provide sec-
ondary prevention, ie evidence-based interventions that reduce the much lower among patients who smoke following a
risk of limb-threatening or life-threatening thrombotic com- revascularisation procedure.5plications.
The increased cancer risk from smoking and the
adverse effects on lung function persist for many years
after a long-term smoker gives up cigarettes, but the
excess risk of cardiovascular disease (i.e. death andischaemia, acute myocardial ischaemia or sudden
death. The term ‘‘conservative therapy’’, often used by nonfatal myocardial infarction) diminishes relatively
quickly after smoking cessation, e.g. within 2–4 years.6vascular surgeons, is perhaps no longer appropriate
for patients with IC because it implies a clinical man- Thus, patients with IC can be reassured that the vas-
cular benefits of smoking cessation accrue almost im-agement based largely on passive surveillance and
exercise, without surgical or intensive medical inter- mediately, even though the carcinogenic risk lingers
on for at least another decade. This justifies a morevention. This is particularly inappropriate now that
randomised controlled trials have demonstrated the intensive, evidence-based approach to smoking ces-
sation in PAD patients, making use of treatments thatefficacy and safety of a range of medical therapies for
prolongation of survival among patients with ath- have been shown to relieve symptoms of nicotine
withdrawal and improve quit rates among motivatederosclerotic vascular disease, whether or not this dis-
ease manifests initially as cardiac, peripheral or but nicotine-dependent smokers.
Strategies to help patients quit smoking should gocerebral symptoms. The purpose of this review is to
provide an update on the evidence behind effective beyond simple advice and retribution. Because nic-
otine is a drug of dependence (it is the other con-secondary prevention that improves outcome (but not
exercise-induced symptoms) in this high-risk patient stituents of cigarettes that promote atheroma),
spontaneous quit rates are low even among patientsgroup.
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Fig. 3. The Cochrane review group has undertaken a meta-analysis of over 50 randomised controlled trials of nicotine replacement therapy
(NRT)7 and 3 studies with bupropion.8 Both treatments in motivated patients effectively double the quit rate at 1 year, relative to placebo.
who want to give-up (<5% per year). Psychological shown that aspirin, either as monotherapy or in com-
bination with dipyridamole, delays the progression ofcounselling and support improves cessation rates mod-
established PAD, as assessed by serial angiography,estly, but there have been over 50 randomised, placebo-
and decreases the need for surgical revascularis-controlled trials (RCTs) using various forms of nicotine
ation.9,10 Aspirin also improves patency rates followingreplacement therapy (NRT) showing that quit rates
revascularisation.11 The standard dose of aspirin forafter 1 year are doubled among motivated patients
secondary prevention is usually 75–150 mg daily;given active NRT and educational support. The
higher doses of aspirin provide no clear therapeuticCochrane database has undertaken a meta-analysis of
advantage but the incidence of gastrointestinal side-RCTs of NRT and shown beyond doubt that this
effects is much higher. For example, in the secondaryapproach is safe and effective (Fig. 3).7 There has also
prevention of transient ischaemic attacks, aspirinbeen a Cochrane meta-analysis of a smaller number
30 mg was no less effective than aspirin 283 mg, butof RCTs using an oral agent, the antidepressant bu-
had fewer complications.12propion, as a 2-month course of therapy to relieve
The CAPRIRE study13 showed that, overall, the ad-nicotine withdrawal symptoms (Fig. 3).8 It too is effect-
vantages of clopidogrel over aspirin are modest (<9%),ive but the weight of evidence favours NRT as the
but in the subgroup with PAD clopidogrel had a morepreferred first-line option.
impressive effect (Fig. 4). Thus, in patients with IC
newer antiplatelet agents may be preferred instead of
aspirin for secondary prevention, especially among
Anti-platelet therapy and warfarin those patients who are intolerant or allergic to aspirin.
More recent studies in patients with unstable angina
Aspirin therapy, while having no effect on walking suggest that the benefits of clopidogrel and aspirin
distance or symptom status, does seem to modify the are additive,14 implying that combination anti-platelet
therapy will become more widely established. Pre-clinical course of PAD. Large randomised trials have
Eur J Vasc Endovasc Surg Vol 23, February 2002
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the 4S study with simvastatin16 and the CARE study
with pravastatin.17 These drugs block the rate-limiting
enzyme in endogenous cholesterol biosynthesis in the
liver (HMG-CoA reductase); less than 20% of circu-
lating cholesterol (as opposed to fat, i.e. triglycerides)
is derived from the diet. Therapy with simvastatin
20–40 mg or pravastatin 40 mg at night (most endo-
genous cholesterol biosynthesis occurs overnight),
among patients with symptomatic CHD, reduced
circulating cholesterol levels, on average, by 32%,
40
Clopidogrel better
–40
Aspirin better
3020100–10–20–30
Mean and
95% CI
Stroke
MI
PAD
All patients
with 30–40% reductions in fatal and non-fatal CHD
Fig. 4. In the CAPRIE study,13 patients with PAD seem to obtain an events.16,17 Stroke risk was also reduced in both the 4S
even greater benefit with clopidogrel (relative to aspirin) compared
and CARE trials (20% reduction), suggesting that thewith overall results for the entire study population.
statin had extra-cardiac effects on the progression of
atherosclerotic disease elsewhere in the circulation.vious combination strategies found only a marginal
There seems to be a curvi–linear relationship be-advantage in adding dipyridamole to aspirin following
tween cholesterol reduction and improved survival inTIA, but clopidogrel+aspirin seems to be significantly
the 4S and CARE trials, i.e. a relationship of di-more effective, at least following an episode of unstable
minishing return with ever-lower levels of cholesterol.angina (relative risk reduction was 20% vs aspirin
Simvastatin and pravastatin are the only statins li-alone for the composite primary endpoint of cardio-
censed for secondary prevention; newer statins, with-vascular death, myocardial infarction and stroke at 1
out mortality evidence, are licensed only foryear14).
‘‘cholersterol reduction’’, and the recent withdrawalAmong patients with non-valvular atrial fibrillation
of cerivastatin highlights the incomplete safety data-(AF) and IC, in whom there is a particular risk of
base for newer statin drugs.acute embolic lower limb ischaemia and stroke, RCTs
Relatively little is published about the subgroups ofand meta-analyses have clearly indicated that anti-
patients in these trials with PAD; only 4% of par-coagulation with warfarin (target INR 2.5–3.5) is
ticipants in the 4S study had IC at baseline.16 Never-superior to aspirin,15 although in elderly patients the
theless, statin therapy is associated with plaquebenefits of warfarin need to be carefully balanced on
stabilisation and useful anti-inflammatory effects inan individual patient basis against the risk of life-
the vessel wall, and there is nothing to suggest thatthreatening bleeding complications, e.g. following a
this pharmacological effect is confined to disease insimple fall or via gastrointestinal blood loss. AF affects
the coronary arteries.3–5% of the entire population over 60 years old, and
A Cochrane meta-analysis of lipid-lowering therapyphysicians routinely consider anticoagulation in
in patients with PAD concluded that cholesterol re-patients with AF under the age of 85 years, even in
duction probably reduces mortality,18 and there is evi-the absence of thromboembolic symptoms, assuming
dence that statins may alter the clinical course of PAD.the individual patient is otherwise mobile, reasonably
For example, an analysis of the 4S study showedwell and able to comply with warfarin therapy and
that the incidence of ‘‘new or worsening’’ IC wasmonitoring. There is no evidence to support the routine
significantly lower in CHD patients treated with sim-use of warfarin (instead of aspirin or in addition to
vastatin (Fig. 5).19 Thus, patients with symptomaticaspirin) for secondary prevention in IC patients in
PAD and hypercholesterolaemia (total cholesterolsinus rhythm, although in some patients short-term
>5 mmol/L), as well as those with overt CHD, shouldanticoagulation may be considered surgically bene-
be treated with a statin to achieve target LDL-cho-ficial to avoid lower-limb complications post-op-
lesterol levels <3 mmol/L. The benefits apply equallyeratively.
to men and women; those above and below 65 years
of age; and especially patients with diabetes.
Lipid lowering therapy
Large randomised, placebo-controlled clinical trials in Blood pressure reduction
patients with established CHD have clearly dem-
onstrated major reductions in cardiac (and non-car- The Framingham epidemiological study provides ob-
servational evidence that patients with high blooddiac) morbidity and mortality with statin therapy, e.g.
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control (BP <140/85 mmHg) among treated hyper-
tensive patients are relatively low (<30%), even in
specialist centres. This partly reflects the difficulty in
lowering systolic BP, especially in the elderly, and it
also reflects issues of tolerability and compliance with
multiple antihypertensive therapies. Many patients
develop postural symptoms or other drug-related side
effects which limit the capacity to up-titrate medication
in pursuit of target BP levels. Nevertheless, even mod-
est BP reductions confer large clinical benefits and
clinicians should strive for lower levels of treated BP
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Fig. 5. Simvastatin-treated patients in the 4S study had a lower therapy for individual patients.incidence of ‘‘new or worsening’’ IC, consistent with an effect of
the statin on plaque stabilisation and regression in the legs.19
pressure (BP) are at greater risk of developing IC (Fig. Angiotensin converting enzyme (ACE) inhibitors –
effects beyond BP reduction6).20 Isolated systolic hypertension (ISH), in particular,
is very common in the elderly and closely associated
It has been well established for a number of years thatpathophysiologically with increased arterial stiffness,
pressure-wave reflection and an increased systolic BP ACE inhibitors prolong survival and reduce symptoms
and hospitalisation rates among patients with allload on the heart causing LV hypertrophy. Large
placebo-controlled intervention studies over the last grades of heart failure, but the recent HOPE study
showed that long-term treatment with ramipril (com-20 years, randomising patients at ever-lower levels
of BP, have shown conclusively that even modest pared to placebo) as add-on to other cardiovascular
therapies confers significant reductions in morbidityreductions in BP (eg 10/5 mmHg with monotherapy)
translate into significant reductions in stroke (40%) and mortality among patients with CHD (and
asymptomatic patients with diabetes plus one otherand CHD (16%) mortality, and total cardiovascular
mortality (30%).21 More recently, the Hypertension risk factor) who do not have left ventricular (LV)
dysfunction.24 Some 9541 patients were randomised toOptimal Treatment (HOT) trial showed that, among
treated hypertensives, aiming for lower target BP levels ramipril 10 mg or matching placebo in 19 countries
for a mean follow-up period of 4–6 years. The primary(<80 mmHg diastolic) achieves maximum cardio-
vascular protection.22 Even non-hypertensive patients endpoint of combined cardiovascular death, MI and
stroke was reduced by 22% (p<0.000002); and all-treated with BP-lowering therapy, e.g. following a
stroke, also benefit from added secondary prevention.23 cause mortality was 17% lower (p<0.0035). Secondary
endpoints included significantly fewer ramipril-Thus, the modern definition of hypertension (‘‘that
level of BP above which treatment does more good treated patients needing a revascularisation procedure
(cardiac or peripheral) (relative risk reduction 12%,than harm’’) is steadily reaching lower thresholds of BP
that were previously regarded as within the ‘‘normal’’ p<0.0015). Vitamin E, which was also evaluated in the
HOPE trial (vs placebo) using a 2×2 factorial design,range. The intervention trials in hypertension have
generally not included lower-limb endpoints, but it is had no significant effects.
A subgroup analysis of 4046 subjects with PAD inclear that high BP is a risk factor for IC and that
ISH in particular (commonly associated with PAD) the HOPE trial suggests that this particular subgroup
gains even more benefit from ramipril compared withpredisposes to arterial stiffness, cardiac hypertrophy
and progression of the atherosclerotic process. Tight those without PAD (Fig. 7).
This very large and well conducted clinical trialBP control (target BP <140/85 mmHg) is therefore an
essential aspect of management in elderly patients provides persuasive evidence that effectively any
patient with symptomatic atherosclerotic disease (orwith IC, and this will inevitably require combination
drug therapy. Diuretics are ideal first-line treatments asymptomatic diabetics with one other risk factor),
including those with IC, should be treated with anfor elderly patients with ISH. The risk of underlying
renovascular disease should always be considered in ACE inhibitor as part of secondary prevention, ir-
respective of other background medical therapies andpatients with PAD, treatment-resistant hypertension
and mild renal impairment, especially smokers. even if they are normotensive with normal LV function.
Because patients in the HOPE study were alreadySuccess rates in achieving the current targets for BP
Eur J Vasc Endovasc Surg Vol 23, February 2002
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Fig. 6. The relationship between BP and IC. Eastimated 4-year probability of intermittent claudication in 70-year old men in the Framingham
Heart study according to category of normal (NI), high-normal (high NI), stage 1 and stage 2 hypertension. The multiplicative interaction
between BP and other risk factors is also illustrated. Reproduced from [20].
by the recent PROGRESS study,23 in which non-hyper-
tensive patients received considerable benefits from
secondary prevention using ACE inhibitor based ther-
apy (perindopril) which could not be solely at-
tributable to the antihypertensive effect. For example,
perindopril-based therapy reduced the risk of re-
current stroke by 32% and 27% in hypertensive and
non-hypertensive patients, respectively, and the cor-1.2
22.0
Relative risk in Ramipril group
0.6 1.00.8
15.3
Incidence
of composite
outcome in
placebo group
4046
5251
No. of
patients
PAD
No PAD
responding reductions in all major vascular events
were 29% and 24% (p<0.001).23Fig. 7. The results of the HOPE study24 according to whether patients
had PAD or not at baseline. The benefits of ramipril 10 mg/d were Thus, the significance of the HOPE study (a single
at least as good (if not better) in the PAD subgroup. but very large, well conducted trial) would suggest that
all patients with symptomatic PAD, where possible,
should receive an ACE inhibitor in addition to their
other cardiovascular therapies. ACE inhibitors are con-treated with various BP-lowering and other cardio-
tra-indicated in patients with bilateral renal arteryvascular therapies, e.g. anti-anginals, baseline BP prior
stenosis (RAS), or unilateral RAS in a single func-to the addition of ramipril or placebo was relatively
tioning kidney. They should otherwise be used withgood (139/79 mmHg). Only 46% of study participants
caution in the presence of renal impairment and ifhad a prior diagnosis of hypertension. The net anti-
there is a suspicion of possible RAS. Because thehypertensive effect of ramipril was only 2/3 mmHg,
incidence of RAS is quite high in the PAD population,which seems unlikely to explain the considerable be-
it is therefore essential to use a low starting dose andnefits in terms of prolonged survival. Thus, it seems
to check the serum electrolytes 1 week and 1 monthlikely that ACE inhibitors confer protective effects on
after starting or increasing ACE inhibitor therapy. Inthe atherosclerotic process that are clinically important,
the HOPE trial (and other pragmatic ACE inhibitore.g. improved endothelial function, over and above
studies), where patients were not screened in detail tothe benefits attributable to BP reduction.
exclude RAS, the actual incidence of complicationsThe notion of non-BP-mediated benefits of ACE
inhibitors in secondary prevention is also supported (e.g. renal failure) was surprisingly low.
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Table 1.Glycaemic control in diabetes
Experimental studies of potential new secondary prevention
therapies are focusing on:Patients with diabetes tend to have more severe, often
distal and diffuse, multivessel PAD that is less amen- • reversing endothelial dysfunction (an early hallmark of
arterial disease) by restoring normal vasorelaxation,able to revascularisation, and restenosis in diabetics is
antithrombotic mechanisms and inter-cellular adhesion;a particular problem following angioplasty.25 The risk • plaque stabilisation and regression via blocking inflammatory
of lower limb ulceration is exacerbated by microvessel processes;
• prevention of neointimal hyperplasia and restenosis followingdisease and neuropathy, as well as PAD, and am-
balloon injury during angioplasty;putation rates among diabetics (mainly distal am- • changes in intima-media thickness to reflect slowing of the
putations) are 40-fold higher than in age-matched atherosclerotic progression;
• use of crosslink breakers to inhibit advanced glycosylationnondiabetic controls.26
(AGE) processes in the mediation of vascular ageing andType 2 diabetes is very much a clinical syndrome in vascular stiffness.
which hyperglycaemia is only one facet; other features
include insulin resistance, hypertension, obesity and
dyslipidaemia. The major benefit of tight glycaemic
control is in the prevention of microangiopathy (ret- Therapeutic Targets for New Vascular Disease-
inopathy, nephropathy, neuropathy), whereas tight BP modifying Agents: the Future of Secondary
control has a much greater impact on macrovascular Prevention
complications and death rates. For example, in the UK
Prospective Diabetes Study (UKPDS), every 10 mmHg RCTs of sufficient size and duration to assess treatment
reduction in systolic BP was associated with a 12% effects on morbidity and mortality are the ultimate
reduction in any diabetes-related complication; 15% benchmark standard for establishing the role of a new
reduction in death related to diabetes; 11% reduction drug in long-term secondary prevention. But advances
in MI; and 13% reduction in microvascular com- in the understanding of how atherosclerotic disease
plications.27 Thus, BP reduction ameliorates micro- develops and progresses has identified several target
vessel complications and (unlike tight glycaemic con- mechanisms for new agents aimed at achieving de-
trol) reduces diabetes-related deaths. layed progression, plaque stabilisation and even re-
Increasing HbA1c is still a risk factor for large vessel gression of arterial disease (Table 1).
complications,28 but the principal benefits of glucose For example, recent evidence has shown using ultra-
reduction are in microvessel protection and, for the sound that ramipril treatment in the HOPE study
lower limb, prevention of neuropathy and secondary retards the progression of atherosclerosis, as dem-
complications such as ulceration and infection. For onstrated by the annual increase in carotid intima-
every 1% increase in HbA1c there is a 28% increased media thickness;29 adjuvant anti-platelet therapy
risk of death, independent of age, BP, serum cholesterol (clopidogrel+aspirin) provides improved outcomes
and smoking status.28 More importantly, however, over following percutaneous angioplasty;30 and statins im-
80% of the population excess mortality risk associated prove endothelial function, independent of their lipid-
with HbA1c occurs in men with HbA1c concentrations lowering effects.31 In addition, there is recent evidence
of 5–6.9% (which is the majority of the population and that cilostazol (a symptom relieving drug in IC) inhibits
includes people who, by definition, are not diabetic).28 neointimal hyperplasia and restores endothelial func-
tion following balloon injury,32 and increases vascular
endothelial growth factor (VEGF) mediated collateral
vessel formation.33
Multiplicative interaction of risk factors
Conclusions
Most patients with IC have more than one modifiable
risk factor, and it is important to remember that risk IC is a common and disabling symptom associated
with increased cardiovascular mortality due to acutefactors have greater-than-additive effects on overall
risk (Fig. 6).20 Thus, a clinical strategy of multiple thrombotic complications superimposed on a ruptured
plaque causing limb-threatening or life-threateningrisk factor intervention is likely to yield significantly
greater benefits than incomplete treatment with tar- ischaemia. The overall management of patients with
IC should include treatments (medical, surgical andgeted secondary prevention of single risk factors.
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